Sun Pharma deal for lerodalcibep worldwide (ex US, China) seen lifting revenue potential
Axis and DAM Capital say Sun Pharma’s exclusive licensing with LIB Therapeutics for lerodalcibep could generate over $700m in peak sales; shares rose up to 1.32% and analysts rate it a buy with median target 2,150 rupees.